Larix

What Larix does

Larix is a Denmark-based clinical research services firm headquartered in Herlev, founded in 2001, with 51-100 employees. The company delivers statistics, data management, and data monitoring services to pharmaceutical, biotechnology, and medical device sponsors. Associated operational data indicates a global clinical research organization operating across APAC, Europe, North America, and South America with 1,580+ studies completed across Phase I-IV and 33,189+ patients enrolled across 610 sites.

The service portfolio spans three engagement models: Full-Service CRO Partnership (end-to-end trial management with experienced personnel and advanced technology for clinical data management), Functional Service Provision (FSP, providing flexible governance and management tailored to client requirements), and Consulting Support (clinical development expertise to streamline trial execution). Core technical capabilities include Electronic Data Capture (EDC) systems management, AI-supported pharmacovigilance for safety data oversight, and nine service modules covering clinical trial operations, medical writing, pharmacovigilance, quality assurance, regulatory affairs, statistics and programming, data management with HEOR & market access, real-world evidence, and toxicology.

The company monetizes through quote-based professional services and managed services contracts negotiated via RFP/RFI processes, targeting pharmaceutical, biotechnology, and medical device companies as primary verticals, with secondary exposure to cosmetic, agrifood, and veterinary sectors. Therapeutic-area specialization focuses on oncology, rare diseases, and central nervous system (CNS) disorders. Leadership includes Charlotte Olesen as Director of Clinical Operations. Revenue, funding, ownership, and financial performance are not publicly disclosed.

Name

Larix

Legal name

Aixial Group

Website

https://larix.dk

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

51–100 employees

Short description

Larix is a Denmark-based clinical research services firm providing statistics, data management, and data monitoring for pharmaceutical, biotechnology, and medical device sponsors globally, with 1,580+ studies completed across 610 sites.

Ownership category

akta.pro rank

Product category

Clinical Research Services (CRO)

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK)

Keywords

• Clinical data management
• Clinical trial services
• Pharmacovigilance monitoring
• Biostatistics programming
• Regulatory affairs consulting

Headquarters

HQ city

Herlev

HQ country

Denmark

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Full-Service CRO Partnership: Comprehensive clinical research services including end-to-end trial management, data management, and regulatory support delivered as a complete package.
2. Functional Service Provision (FSP): Flexible FSP model providing governance, management, and partnership services tailored to client requirements with adaptable engagement as partnerships evolve.
3. Consulting Services: Clinical development capabilities and integrated consulting expertise for streamlining development at every step.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Larix provides statistics, data management, and data monitoring services to pharmaceutical, biotechnology, and medical device companies. The company delivers clinical research organisation (CRO) services across clinical trial operations, biostatistics, medical writing, pharmacovigilance, regulatory affairs, quality assurance, and real-world evidence, offered through full-service, functional service provision (FSP), and consulting engagement models for Phase I-IV clinical trials.

Product overview

Aixial Group is a global Clinical Research Organisation (CRO) offering a comprehensive portfolio of clinical trial services. The company operates through three core engagement models: Full-Service CRO Partnership (providing experienced personnel and advanced technology for clinical data management), Functional Service Provision (FSP, offering flexible, tailored governance and partnership management), and Consulting Support (delivering integrated expertise to streamline clinical development). The service portfolio encompasses 9 core areas including Clinical Trial Operations, Medical Writing, Pharmacovigilance, Quality Assurance, Regulatory Affairs, Statistics and Programming, Data Management (including HEOR and market access), Real-World Evidence, and Toxicology. The company specializes in therapeutic areas such as Oncology, Rare Diseases, Central Nervous System, and other specialty therapeutics, conducting studies across modalities including Assay, Drug, Device, Diagnostic, Nutraceutical, and Cosmetic interventions.

Differentiator

Problem solved

Functional benefit

Products and services

• Full-Service CRO Partnership A full-service CRO partnership providing experienced personnel and advanced technology for clinical data management, offered to sponsors seeking end-to-end trial outsourcing.
• Functional Service Provision (FSP) Flexible FSP model offering governance, management, and partnership services tailored to client requirements, with the engagement scope adapting as the partnership evolves.
• Consulting Support Clinical development capabilities and integrated consulting expertise designed to streamline development at every step in a faster and more cost-effective way.
• Clinical Trial Operations End-to-end clinical trial operations including biometrics, clinical operations, and study management for Phase I-IV trials.
• Medical Writing Professional medical writing services for clinical documentation and regulatory submissions.
• Pharmacovigilance Safety monitoring and pharmacovigilance services, including AI-supported safety data management, consistency, and oversight, to ensure compliance and patient safety.
• Quality Assurance Quality assurance services to maintain compliance with regulatory standards across clinical operations.
• Regulatory Affairs Regulatory affairs expertise to navigate complex approval processes and submissions across regions.
• Statistics and Programming Statistical analysis and programming services for clinical trial data.
• Data Management Clinical data management services including HEOR (Health Economics and Outcomes Research) and market access support.
• Real-World Evidence Real-world evidence studies and clinical supply chain services.
• Toxicology Toxicology expertise for preclinical and clinical safety assessment.

Quantifiable outcome

• 1,580+ studies completed across Phase I-IV
• +2 more outcomes

Segments9 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators4 records

Recent moves4 records

Expansion highlights5 records

Broad incumbents

• Parexel International: Large global CRO with deep biostatistics, data management, and pharmacovigilance services — directly overlapping with Larix's specialty, but delivered at much greater scale and global reach.
• IQVIA: Largest global CRO and life-sciences technology provider. Competes with Larix for Full-Service and FSP engagements but at vastly greater scale, with overlapping biometrics and pharmacovigilance offerings.
• ICON plc: Top-tier global CRO (post-PRA Health Sciences) with full Phase I–IV and FSP capabilities across all major therapeutic areas. Represents the upper-scale competitive benchmark for Larix's service portfolio.
• Charles River Laboratories: Global CRO with extensive biometrics, clinical trial, and safety/pharmacovigilance offerings. Overlaps with Larix's data-management and clinical-operations services as part of a much broader preclinical and clinical portfolio.

Direct peers

• Cytel: Specialty biostatistics and clinical data science CRO serving pharma and biotech. Directly comparable to Larix's statistics-and-data-management focus, with a similar specialty rather than full-service model.
• Premier Research: Mid-sized CRO with strong focus on oncology, rare disease, and CNS — a near-identical therapeutic-area footprint to Larix and similar service offering across clinical operations, biometrics, and regulatory.
• Clinipace Worldwide: Mid-sized CRO offering Full-Service, FSP, and consulting with therapeutic emphasis on oncology and rare disease. Operates in a similar size band and service model as Larix.
• Worldwide Clinical Trials: Mid-market global CRO providing Full-Service and FSP across Phase I–IV, with therapeutic focus in CNS, oncology, and rare disease. Comparable scale, model mix, and therapeutic emphasis to Larix.
• Aixial Group: Global CRO offering Full-Service, FSP, and consulting across oncology, rare disease, and CNS. Directly comparable service portfolio and operating model to Larix; the company data is in fact largely drawn from Aixial, indicating an operational/parent linkage between the two entities.
• Rho: US-based specialty CRO with deep biostatistics, data management, and regulatory capabilities for pharma/biotech sponsors. Closely matches Larix's biometrics-and-data-management positioning and target customer base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/larix-aps

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Larix